These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 25186062)

  • 1. Rivaroxaban as an effective treatment for recurrent superficial thrombophlebitis related to primary antiphospholipid syndrome.
    Bachmeyer C; Elalamy I
    Clin Exp Dermatol; 2014 Oct; 39(7):840-1. PubMed ID: 25186062
    [No Abstract]   [Full Text] [Related]  

  • 2. Rivaroxaban in acute coronary syndromes--is it prime time?
    Asrar ul Haq M; van Gaal WJ
    Expert Rev Cardiovasc Ther; 2014 Jun; 12(6):649-58. PubMed ID: 24746010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rivaroxaban for treatment of HIT: a riveting first experience.
    Linkins LA; Warkentin TE
    Thromb Res; 2015 Jan; 135(1):1-2. PubMed ID: 25466840
    [No Abstract]   [Full Text] [Related]  

  • 4. First experiences with the use of rivaroxaban in the treatment of heparin-induced thrombocytopenia.
    Ng HJ; Than H; Teo EC
    Thromb Res; 2015 Jan; 135(1):205-7. PubMed ID: 24974053
    [No Abstract]   [Full Text] [Related]  

  • 5. Effectiveness of rivaroxaban for thromboprophylaxis of prosthetic heart valves in a porcine heterotopic valve model.
    Greiten LE; McKellar SH; Rysavy J; Schaff HV
    Eur J Cardiothorac Surg; 2014 May; 45(5):914-9. PubMed ID: 24306948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Initial experience with rivaroxaban in mechanical valve prosthesis in an animal model.
    Aramendi JI; Mestres CA
    Eur J Cardiothorac Surg; 2014 May; 45(5):920-1. PubMed ID: 24186922
    [No Abstract]   [Full Text] [Related]  

  • 7. Use of rivaroxaban could trim hospital spending in treating pulmonary embolism.
    Caffrey MK
    Am J Manag Care; 2014 May; 20(8 Spec No.):E12. PubMed ID: 25617931
    [No Abstract]   [Full Text] [Related]  

  • 8. Outcomes in patients with nontriple antiphospholipid syndrome (APS) anticoagulated with rivaroxaban.
    Htut TW; Milne D; Khan MM; Watson HG
    Int J Lab Hematol; 2021 Oct; 43(5):e252-e253. PubMed ID: 33470532
    [No Abstract]   [Full Text] [Related]  

  • 9. Rivaroxaban prevents painful cutaneous infarctions in livedoid vasculopathy.
    Kerk N; Drabik A; Luger TA; Schneider SW; Goerge T
    Br J Dermatol; 2013 Apr; 168(4):898-9. PubMed ID: 23106384
    [No Abstract]   [Full Text] [Related]  

  • 10. A new era in secondary prevention after acute coronary syndrome.
    Roe MT; Ohman EM
    N Engl J Med; 2012 Jan; 366(1):85-7. PubMed ID: 22077849
    [No Abstract]   [Full Text] [Related]  

  • 11. Rivaroxaban and false positive lupus anticoagulant testing.
    Merriman E; Kaplan Z; Butler J; Malan E; Gan E; Tran H
    Thromb Haemost; 2011 Feb; 105(2):385-6. PubMed ID: 21103666
    [No Abstract]   [Full Text] [Related]  

  • 12. Meta-analysis of efficacy and safety of rivaroxaban compared with warfarin or dabigatran in patients undergoing catheter ablation for atrial fibrillation.
    Aryal MR; Ukaigwe A; Pandit A; Karmacharya P; Pradhan R; Mainali NR; Pathak R; Jalota L; Bhandari Y; Donato A
    Am J Cardiol; 2014 Aug; 114(4):577-82. PubMed ID: 24998087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rivaroxaban and stroke prevention in patients with atrial fibrillation: new evidence.
    Martínez-Rubio A; Dan GA; Kaski JC
    Expert Rev Cardiovasc Ther; 2014 Aug; 12(8):933-47. PubMed ID: 24948333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Comparison of the safety of rivaroxaban versus dabigatran therapy in patients with persistent atrial fibrillation].
    Gorzelak-Pabiś P; Duraj I; Szlagowska L; Ciastkowska A; Broncel M
    Pol Merkur Lekarski; 2014 Nov; 37(221):261-4. PubMed ID: 25546985
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rivaroxaban use in patients with antiphospholipid syndrome and previous venous thromboembolism.
    Sciascia S; Breen K; Hunt BJ
    Blood Coagul Fibrinolysis; 2015 Jun; 26(4):476-7. PubMed ID: 25923780
    [No Abstract]   [Full Text] [Related]  

  • 16. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study.
    Agnelli G; Gallus A; Goldhaber SZ; Haas S; Huisman MV; Hull RD; Kakkar AK; Misselwitz F; Schellong S;
    Circulation; 2007 Jul; 116(2):180-7. PubMed ID: 17576867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A cost-analysis model for anticoagulant treatment in the hospital setting.
    Mody SH; Huynh L; Zhuo DY; Tran KN; Lefebvre P; Bookhart B
    J Med Econ; 2014 Jul; 17(7):492-8. PubMed ID: 24773068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transition from apixaban to warfarin--addressing excess stroke, systemic embolism, and major bleeding.
    Cairns JA; Weitz JI
    Am Heart J; 2015 Jan; 169(1):1-3. PubMed ID: 25497240
    [No Abstract]   [Full Text] [Related]  

  • 19. Rivaroxaban Versus Vitamin K Antagonist in Antiphospholipid Syndrome.
    Cortés-Hernández J
    Ann Intern Med; 2020 Sep; 173(6):505-506. PubMed ID: 32926827
    [No Abstract]   [Full Text] [Related]  

  • 20. Help prevent Afib-related stroke. New anticoagulants for atrial fibrillation prove as effective, or even better than, warfarin--and easier to use.
    Duke Med Health News; 2014 Sep; 20(9):3. PubMed ID: 25358137
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.